Unpacking Antipsychotic Use in Adults with Intellectual and Developmental Disabilities
"A closer look at prescribing trends, potential risks, and the crucial need for tailored care in vulnerable populations."
Antipsychotic medications play a complex role in managing the health of adults with intellectual and developmental disabilities (IDD). While these drugs can be essential for treating certain psychiatric conditions, their use is often debated, especially when there's no clear psychiatric diagnosis. Concerns arise due to potential side effects and limited proof of their effectiveness in these situations. This article dives into a study that examines how antipsychotics are being used among adults with IDD in Ontario, Canada, shedding light on the characteristics of those who receive these medications, with or without a formal psychiatric diagnosis.
The original research, published in The Canadian Journal of Psychiatry, used a comprehensive population-based approach to understand antipsychotic prescribing patterns. Researchers analyzed data from over 50,000 adults with IDD, tracking their medication use and comparing the profiles of individuals with and without documented psychiatric conditions.
This article translates the key findings of this study into an accessible format, highlighting the prevalence of antipsychotic use, the factors associated with its use, and the implications for ensuring appropriate care for this vulnerable population.
From Serendipitous Discoveries to Drug Generations
Antipsychotic medications were discovered through largely serendipitous observations of their psychiatric effects. They are broadly classified as classical or typical antipsychotics, including phenothiazines and butyrophenones, and atypical antipsychotics, which include benzamides. Drug development later progressed through first-generation agents such as haloperidol, second-generation agents such as olanzapine and clozapine, and a possible third generation represented by aripiprazole, with efforts focused on efficacy and tolerability. In people with intellectual disabilities, antipsychotics have a documented history of use, overuse, and misuse.
What's Driving Antipsychotic Prescriptions for Adults with IDD?
The study found that a significant portion of adults with IDD – 39.2% overall – were prescribed antipsychotic medications. This rate jumped to 56.4% for those living in group homes. Even more striking, almost 29% of those receiving antipsychotics didn't have a documented psychiatric diagnosis. This raises critical questions about why these medications are being used in the absence of a clear psychiatric need.
- Age: Those without a psychiatric diagnosis tended to be older.
- Prior Medication Use: They were less likely to have used antidepressants or benzodiazepines in the previous year.
- Healthcare Utilization: They had lower rates of ambulatory and acute care visits.
Evidence on Behaviors That Challenge
A July 2025 review describes behaviors that challenge, including aggression and self-injury, as common among individuals with intellectual disabilities and notes their substantial effect on quality of life. The review examines the use of antipsychotic medication as a pharmacological approach to managing these behaviors. Its search covered studies published from January 1990 through June 2024, including randomized controlled trials and cross-sectional or longitudinal observational studies. Other recent work includes a 2024 systematic review and cross-sectional study of antipsychotic medication in people with intellectual disability and schizophrenia.
Moving Forward: Ensuring Appropriate Prescribing Practices
This study serves as a call to action. It highlights the urgent need for careful attention to how antipsychotics are prescribed and monitored in adults with IDD. By promoting evidence-based practices, comprehensive assessments, and individualized treatment plans, healthcare professionals can help ensure that these medications are used appropriately and safely, improving the quality of life for individuals with IDD.
Improving Prescribing Oversight
Future work is focused on improving the quality of antipsychotic prescribing and its long-term management for adults with intellectual disability. One study used a secondary analysis of a Prescribing Observatory for Mental Health audit to assess requests from intellectual disability services to primary care for repeat antipsychotic prescriptions; the analysis included 46 requests. Research has also examined psychotropic medication use among adults with intellectual disability, including antipsychotics, antidepressants, anxiolytics, hypnotics and sedatives, and psychostimulants. These findings support continued attention to prescribing practices and long-term management of challenging behaviors.
Effectiveness, Tolerability, and Treatment Processes
A chart review examined antipsychotic use, real-world effectiveness and tolerability among individuals with intellectual disabilities who had psychosis occurring in the context of genetic variants. The research was largely descriptive, cross-sectional and retrospective, so its findings reflect observed clinical experience rather than a controlled treatment comparison. Another study explored the processes involved when people with intellectual disabilities are prescribed antipsychotic medication. It reported that non-compliance, which is common within the broader psychiatric population, was not observed at the same rate in people with intellectual disabilities.